Medication info
Rinarem Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin)

Rinarem Extended-Release Tablets 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped, biconvex, extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202400571 · Approved 2024.03.18 · Insurance code 645307050

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is prescribed to assist in blood sugar control for patients with type 2 diabetes using both Linagliptin and Metformin. When taken along with diet and exercise, it can help manage blood sugar levels more effectively. This helps prevent complications and maintain a healthy blood sugar state. Taking this medication along with improvements in lifestyle habits provides significant assistance in diabetes management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take one 5/1000 mg extended-release tablet once daily. Patients taking the 2.5/1000 mg extended-release tablet should take two tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, the initial dose of this medicine should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, discontinue this medicine immediately.

Precautions

This medication can rarely cause serious lactic acidosis or hypoglycemia, so caution is required. Patients with allergies to the components of this medication, or those with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis should not use this medication. Administration should also be avoided in patients with severely impaired kidney function or conditions that could affect kidney function such as acute infections, shock, severe trauma, etc. Patients with liver function disorders, gastrointestinal disorders, acute alcohol intoxication, or alcoholism should also refrain from using this medication. Pregnant women or women with a risk of placental dysfunction or preeclampsia should not use this medication. This medication carries a risk of hypoglycemia, so careful dose adjustment and blood sugar monitoring are required when used with insulin or sulfonylureas and other hypoglycemic agents. Due to the risk of lactic acidosis, special caution is needed in cases with risk factors such as dehydration, cardiovascular disease, liver disease, and excessive alcohol consumption. Kidney function should be regularly tested, and if abnormalities are found, consultation with healthcare professionals should be sought immediately. If symptoms of acute pancreatitis or bullous pemphigoid appear, discontinue the medication immediately and consult a physician. This medication should be swallowed whole without crushing, breaking, or chewing, and the tablet shell may pass in your stool, which is normal. This medication may interact with other drugs, so inform your healthcare provider about all medications you are taking. Elderly patients are more likely to have impaired kidney function, so dose adjustments and regular kidney function tests are necessary. Pregnant or breastfeeding women should avoid using this medication, and if pregnancy is planned, consultation with healthcare providers is advised. In cases of overdose, the drug may not be completely absorbed from the gastrointestinal tract, but due to the risk of lactic acidosis, immediate hospital treatment is required. This medication should be stored out of reach of children and protected from moisture.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemia, dysgeusia, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function test, hepatitis, pruritus, erythema, rash, bullous pemphigoid, severe and disability-associated arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reactions, constipation, epigastric pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, dermal lesions, hepatic metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, laceration, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hearing loss, erectile dysfunction, thyroid goiter, anemia, nausea, gastroesophageal reflux disease, headache, drowsiness, weakness, pain, epistaxis, oropharyngeal pain, voice disorder, allergic rhinitis, exertional dyspnea, wet cough, runny nose, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urinary albumin/creatinine ratio, positive urinary leukocytes, decreased hemoglobin, elevated serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, male-pattern baldness, hyperhidrosis, dermatitis, anxiety, confusion, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air or moisture, so it should be stored in a tightly sealed container. Additionally, it is best stored at room temperature, between 1 to 30 degrees Celsius, ensuring it is not too hot or too cold.

Appearance and packaging

Appearance

Yellow, oval-shaped, biconvex, extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.